Fifty Years of Research on Schizophrenia: The Ascendance of the Glutamatergic Synapse

Overview

Journal Am J Psychiatry

Specialty Psychiatry

Date 2020 Dec 1

PMID 33256439

Citations 26

Authors

Joseph T Coyle

W Brad Ruzicka

Darrick T Balu

Affiliations

Soon will be listed here.

Citing Articles

Future Perspectives of NMDAR in CNS Disorders.

Capo T, Rebassa J, Raich I, Lillo J, Badia P, Navarro G Molecules. 2025; 30(4).

PMID: 40005187 PMC: 11857888. DOI: 10.3390/molecules30040877.

A Critical Reappraisal of Haloperidol for Delirium Management in the Intensive Care Unit: Perspective from Psychiatry.

Jiang S, Gunther M J Clin Med. 2025; 14(2).

PMID: 39860443 PMC: 11766117. DOI: 10.3390/jcm14020438.

Early postnatal NMDA receptor ablation in cortical interneurons impairs affective state discrimination and social functioning.

Uehara J, Gomez Acosta M, Bello E, Belforte J Neuropsychopharmacology. 2025; .

PMID: 39833563 DOI: 10.1038/s41386-025-02051-0.

Variations of blood D-serine and D-aspartate homeostasis track psychosis stages.

Rampino A, Garofalo M, Nuzzo T, Favia M, Saltarelli S, Masellis R Schizophrenia (Heidelb). 2024; 10(1):115.

PMID: 39702391 PMC: 11659589. DOI: 10.1038/s41537-024-00537-2.

Mismatch Negativity (MMN) as a Pharmacodynamic/Response Biomarker for NMDA Receptor and Excitatory/Inhibitory Imbalance-Targeted Treatments in Schizophrenia.

Javitt D Adv Neurobiol. 2024; 40:411-451.

PMID: 39562453 DOI: 10.1007/978-3-031-69491-2_15.

References

Lisman J, Coyle J, Green R, Javitt D, Benes F, Heckers S . Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci. 2008; 31(5):234-42. PMC: 2680493. DOI: 10.1016/j.tins.2008.02.005. View

DeLay J, Deniker P . Chlorpromazine and neuroleptic treatments in psychiatry. J Clin Exp Psychopathol. 1956; 17(1):19-24. View

Krystal J, Karper L, Seibyl J, Freeman G, Delaney R, Bremner J . Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 1994; 51(3):199-214. DOI: 10.1001/archpsyc.1994.03950030035004. View

McGowan P, Sasaki A, DAlessio A, Dymov S, Labonte B, Szyf M . Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. Nat Neurosci. 2009; 12(3):342-8. PMC: 2944040. DOI: 10.1038/nn.2270. View

Yurgelun-Todd D, Coyle J, Gruber S, Renshaw P, Silveri M, Amico E . Functional magnetic resonance imaging studies of schizophrenic patients during word production: effects of D-cycloserine. Psychiatry Res. 2005; 138(1):23-31. DOI: 10.1016/j.pscychresns.2004.11.006. View

Yamamori H, Hashimoto R, Fujita Y, Numata S, Yasuda Y, Fujimoto M . Changes in plasma D-serine, L-serine, and glycine levels in treatment-resistant schizophrenia before and after clozapine treatment. Neurosci Lett. 2014; 582:93-8. DOI: 10.1016/j.neulet.2014.08.052. View

Varese F, Smeets F, Drukker M, Lieverse R, Lataster T, Viechtbauer W . Childhood adversities increase the risk of psychosis: a meta-analysis of patient-control, prospective- and cross-sectional cohort studies. Schizophr Bull. 2012; 38(4):661-71. PMC: 3406538. DOI: 10.1093/schbul/sbs050. View

Kristiansen L, Huerta I, Beneyto M, Meador-Woodruff J . NMDA receptors and schizophrenia. Curr Opin Pharmacol. 2006; 7(1):48-55. DOI: 10.1016/j.coph.2006.08.013. View

Davies C, Segre G, Estrade A, Radua J, De Micheli A, Provenzani U . Prenatal and perinatal risk and protective factors for psychosis: a systematic review and meta-analysis. Lancet Psychiatry. 2020; 7(5):399-410. DOI: 10.1016/S2215-0366(20)30057-2. View

10.

Floresco S, Todd C, Grace A . Glutamatergic afferents from the hippocampus to the nucleus accumbens regulate activity of ventral tegmental area dopamine neurons. J Neurosci. 2001; 21(13):4915-22. PMC: 6762358. View

11.

Heckers S, Konradi C . GABAergic mechanisms of hippocampal hyperactivity in schizophrenia. Schizophr Res. 2014; 167(1-3):4-11. PMC: 4402105. DOI: 10.1016/j.schres.2014.09.041. View

12.

Haaf M, Leicht G, Curic S, Mulert C . Glutamatergic Deficits in Schizophrenia - Biomarkers and Pharmacological Interventions within the Ketamine Model. Curr Pharm Biotechnol. 2018; 19(4):293-307. PMC: 6142413. DOI: 10.2174/1389201019666180620112528. View

13.

Coyle J . Substance use disorders and Schizophrenia: a question of shared glutamatergic mechanisms. Neurotox Res. 2007; 10(3-4):221-33. DOI: 10.1007/BF03033359. View

14.

Lehmann H, Ban T . The history of the psychopharmacology of schizophrenia. Can J Psychiatry. 1997; 42(2):152-62. DOI: 10.1177/070674379704200205. View

15.

Singh T, Walters J, Johnstone M, Curtis D, Suvisaari J, Torniainen M . The contribution of rare variants to risk of schizophrenia in individuals with and without intellectual disability. Nat Genet. 2017; 49(8):1167-1173. PMC: 5533219. DOI: 10.1038/ng.3903. View

16.

Johnstone E, Crow T, Frith C, Husband J, Kreel L . Cerebral ventricular size and cognitive impairment in chronic schizophrenia. Lancet. 1976; 2(7992):924-6. DOI: 10.1016/s0140-6736(76)90890-4. View

17.

Goff D, Tsai G, Levitt J, Amico E, Manoach D, Schoenfeld D . A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry. 1999; 56(1):21-7. DOI: 10.1001/archpsyc.56.1.21. View

18.

Coward D . General pharmacology of clozapine. Br J Psychiatry Suppl. 1992; (17):5-11. View

19.

Basu A, Tsai G, Ma C, Ehmsen J, Mustafa A, Han L . Targeted disruption of serine racemase affects glutamatergic neurotransmission and behavior. Mol Psychiatry. 2008; 14(7):719-27. PMC: 2786989. DOI: 10.1038/mp.2008.130. View

20.

Kambeitz J, Abi-Dargham A, Kapur S, Howes O . Alterations in cortical and extrastriatal subcortical dopamine function in schizophrenia: systematic review and meta-analysis of imaging studies. Br J Psychiatry. 2014; 204(6):420-9. DOI: 10.1192/bjp.bp.113.132308. View